Bonjesta and Diclegis are fixed dose combination drug products of doxylamine succinate and pyridoxine hydrochloride, indicated for the treatment of nausea
Background: Bonjesta and Diclegis are fixed dose combinations of doxylamine and pyridoxine approved by the Food and Drug Administration (FDA) for the
The safety and effectiveness of Bonjesta and Diclegis in pediatric patients have not been established (4-5). Related policies. 5HT3
and affordability of prescription medications and consumer health products. (Bonjesta), and carries the same indication as Diclegis.
Compare Bonjesta vs Diclegis head-to-head with other drugs for uses, ratings, cost, side effects and interactions.
Bonjesta received FDA approval in 2024 based on the safety and efficacy data from Diclegis The absorption and action of Bonjesta may be
prevention and treatment of nausea and vomiting associated with chemotherapy and For Diclegis and Bonjesta: adequate therapeutic trial of
Diclegis, except in those sections where there are data and information specific to Bonjesta. (e.g, the Dosage and Administration, Clinical
In other words Bonjesta is a higher dose Diclegis: 1 tablet Bonjesta = 2 tablets Diclegis. The additional 10mg of pyridoxine and doxylamine in Bonjesta is in
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are